Trial expansion delays data on Basilea's anti-fungal treatment

06/27/2010 | Reuters

Basilea Pharmaceutica is uncertain when anti-fungal drug isavuconazole would hit the market after Japanese partner Astellas Pharma expanded a Phase III trial of the treatment, delaying the release of data for as long as 18 months. The Swiss biotech firm faced a major setback late last year after it failed to gain endorsement from the European Medicines Agency for antibiotic ceftobiprole.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Sr. Principal Electrical Engineer - 14000008LR
San Jose, CA